Immune biomarker evaluation of sequential tyrosine kinase inhibitor and nivolumab monotherapies in renal cell carcinoma: the phase I TRIBE trial

Background: Predictive biomarkers for immune checkpoint blockade in the second-line treatment of metastatic renal cell carcinoma (mRCC) are lacking. Materials and methods: Patients with histologically confirmed RCC who started nivolumab after at least 4 months of tyrosine kinase inhibitors (TKIs) we...

Celý popis

Podrobná bibliografie

Hlavní autoři:	K.S. Shohdy, M. Pillai, K.S. Abbas, J. Allison, T. Waddell, E. Darlington, S. Mohammad, S. Hood, S. Atkinson, K. Simpson, D. Morgan, P. Nathan, E. Kilgour, C. Dive, F. Thistlethwaite
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Elsevier 2024-06-01
Edice:	Immuno-Oncology and Technology
Témata:	predictive biomarkers immune checkpoint blockade metastatic renal cell carcinoma nivolumab progression-free survival clinical benefit rate
On-line přístup:	http://www.sciencedirect.com/science/article/pii/S2590018824000091
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!